17β-HSD

Cat. No.

A69110

CAS No.

36150-08-0

Dehydrofalcarinol

Dehydrofalcarinol is a polyacetylene compound that targets 17β-hydroxysteroid dehydrogenase type 11, exhibiting notable anticancer activity. This compound has demonstrated potential in research applications focusing on triple-negative breast cancer, making it a valuable tool for investigating new therapeutic strategies in oncology. Dehydrofalcarinol's unique mechanism of action positions it as a promising candidate for further study in cancer biology.

Cat. No.

A69111

CAS No.

2589-71-1

4'-Hydroxyvalerophenone

Synonyms: 4-Pentanoylphenol; 4-Valerylphenol

4'-Hydroxyvalerophenone is a specific inhibitor of 17β-hydroxysteroid dehydrogenase (17β-HSD), exhibiting an IC50 value of 60.52 μM. This compound plays a significant role in steroid metabolism and can be utilized in various research applications related to hormonal regulation and steroid biosynthesis. Its inhibitory effects make it a valuable tool for studies investigating the role of 17β-HSD in physiological and pathological processes.

Cat. No.

A69112

CAS No.

243638-37-1

17β-HSD5 inhibitor 1

17β-HSD5 inhibitor 1 is a potent inhibitor of 17β-HSD5, demonstrating an IC50 of 2.9 nM in HEK-293 cells that overexpress human 17β-HSD5. This compound is primarily utilized in research applications related to steroid metabolism and is instrumental in studying the modulation of sex steroid biosynthesis. The selective inhibition of 17β-HSD5 can provide insights into its role in various hormonal disorders and therapeutic interventions.

Cat. No.

A69113

CAS No.

1106941-19-8

17β-HSD5 inhibitor 2

17β-HSD5 inhibitor 2 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5), demonstrating an IC50 value of 40 nM. This compound is valuable for research into steroid metabolism and androgen biosynthesis, with potential applications in studying conditions related to hormone regulation and prostate cancer. Its inhibitory action enables the exploration of therapeutic strategies targeting 17β-HSD5 in various biological contexts.

Cat. No.

A77869

CAS No.

2990549-76-1

Steroid sulfatase/17β-HSD1-IN-3

Steroid sulfatase/17β-HSD1-IN-3 is a potent dual inhibitor targeting steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits human STS activity with an IC50 of 27 nM, demonstrating significant efficacy. This compound is suitable for research focused on endometriosis and other estrogen-dependent diseases, facilitating the exploration of therapeutic strategies in these areas.

Cat. No.

A77876

CAS No.

2990549-70-5

Steroid sulfatase/17β-HSD1-IN-1

Steroid sulfatase/17β-HSD1-IN-1 is a potent inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting an IC50 value of 28 nM for human steroid sulfatase in cellular assays. This compound is valuable for investigating estrogen-dependent diseases, making it an important tool for research in hormone-related therapeutic areas. Its specificity and potency support studies aiming to elucidate the role of these enzymes in disease mechanisms.

Cat. No.

A77877

CAS No.

2990549-94-3

Steroid sulfatase/17β-HSD1-IN-4

Steroid sulfatase/17β-HSD1-IN-4 is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits hSTS activity, demonstrating an IC50 value of 63 nM. This compound is valuable for studying endometriosis and other estrogen-dependent diseases, providing insights into the role of steroid metabolism in these conditions.

Cat. No.

B18131

CAS No.

2986319-18-8

S19-1035

S19-1035 is a selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibiting a potent inhibition with an IC50 of 3.04 nM. This compound is valuable for studying the role of AKR1C3 in tumor biology and its potential implications in oncological research. Researchers can utilize S19-1035 to investigate the mechanisms underlying tumor progression and to explore new therapeutic strategies targeting AKR1C3.